Ji-Wei Li1,2, Ya-Jun Li1,2, Mei-Zuo Zhong3, Xian-Ling Liu4, Jin Li1,2, Kun-Lun Li1,2, Xi-Yu Liu1,2, Fang Zhou1,2, Zhou OuYang1,2, Zhong-Yi Sun1,2, Li-Jun Huang1,2, Jun-Qiao He1,2, Hui Zhou1,2, Ping-Yong Yi1,2. 1. Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, Hunan, China. 2. The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China. 3. Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China. 4. Cancer Center of the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Abstract
OBJECTIVES: Nasal-type extranodal natural killer NK/T-cell lymphoma (ENKTCL) is a distinct type of non-Hodgkin lymphoma with poor prognosis. This research aimed to evaluate the efficacy and safety of the GELOXD or P-GEMOXD regimens in patients with ENKTCL. METHODS: Newly diagnosed ENKTCL patients treated with either the GELOXD or the P-GEMOXD regimen were identified from three cancer centers between January 2010 and December 2016. Kaplan-Meier and Cox regression analyses were used to calculate overall survival (OS) and progression-free survival (PFS) and to investigate prognostic factors. RESULTS: One hundred and eighty-four cases were identified from three cancer centers. After 1-5 treatment cycles of GELOXD or P-GEMOXD chemotherapy, 155 (84%) patients showed a complete response (CR). The 3-year OS (73.0% vs 38.2%, P = .001) and PFS (72.8% vs 32.4%, P = .000) rates were significantly higher in early-stage patients compared with advanced-stage patients. A multivariate analysis revealed that patient CR status was a significant independent factor in disease prognosis. Grade 3/4 leukopenia occurred in 43 (23.4%) patients. Major non-hematological toxicities included nausea (n = 117, 63.6%) and vomiting (n = 66, 35.9%). CONCLUSIONS: The GELOXD and P-GEMOXD chemotherapy regimens are well tolerated and provide favorable survival outcomes in patients with ENKTCL.
OBJECTIVES: Nasal-type extranodal natural killer NK/T-cell lymphoma (ENKTCL) is a distinct type of non-Hodgkin lymphoma with poor prognosis. This research aimed to evaluate the efficacy and safety of the GELOXD or P-GEMOXD regimens in patients with ENKTCL. METHODS: Newly diagnosed ENKTCL patients treated with either the GELOXD or the P-GEMOXD regimen were identified from three cancer centers between January 2010 and December 2016. Kaplan-Meier and Cox regression analyses were used to calculate overall survival (OS) and progression-free survival (PFS) and to investigate prognostic factors. RESULTS: One hundred and eighty-four cases were identified from three cancer centers. After 1-5 treatment cycles of GELOXD or P-GEMOXD chemotherapy, 155 (84%) patients showed a complete response (CR). The 3-year OS (73.0% vs 38.2%, P = .001) and PFS (72.8% vs 32.4%, P = .000) rates were significantly higher in early-stage patients compared with advanced-stage patients. A multivariate analysis revealed that patientCR status was a significant independent factor in disease prognosis. Grade 3/4 leukopenia occurred in 43 (23.4%) patients. Major non-hematological toxicities included nausea (n = 117, 63.6%) and vomiting (n = 66, 35.9%). CONCLUSIONS: The GELOXD and P-GEMOXD chemotherapy regimens are well tolerated and provide favorable survival outcomes in patients with ENKTCL.
Authors: X Zheng; X He; Y Yang; X Liu; L L Zhang; B L Qu; Q Z Zhong; L T Qian; X R Hou; X Y Qiao; H Wang; Y Zhu; J Z Cao; J X Wu; T Wu; S Y Zhu; M Shi; L M Xu; H L Zhang; H Su; Y Q Song; J Zhu; Y J Zhang; H Q Huang; Y Wang; F Chen; L Yin; S N Qi; Y X Li Journal: ESMO Open Date: 2021-07-06